–
Closing
–
1D
–
YTD
Market cap
-
52 week high
-
52 week low
-
Volume
-
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
-
Analysts' Rating
-
Price Target (Mean)
-
Total Analysts
2
P/E
-
Operating Margin
-
Beta
-
Revenue Growth (Annual)
1.17%
52 week high
-
52 week low
-
Div. Yield
-
EPS Annual Growth
-
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Mauna Kea Technologies SAS is a medical device company based in France. The Company focuses on eliminating uncertainties related to the diagnosis and treatment of cancer and other diseases thanks to real time in vivo microscopic visualization. The Company’s flagship product is Cellvizio, a confocal laser endomicroscopy platform using microprobes and needles. This technological platform enables to view tissues at cellular level, in real time, during standard procedure. Cellvizio can be used in gastroenterology, pulmonology, or urology. The Company markets its technological platform in more than 40 countries, including the United States, Europe, Japan, China, South Korea as well as several Latin American countries.
